Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CRAT | P43155 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11506429 | 0.91 | PLA2G2C (0.59) | TAS1R3TAS1R1PLA2G2CPLA2G2A | |
| SCHEMBL8367402 | 0.90 | TAS1R3 (0.46) | TAS1R3TAS1R1PLA2G2CPLA2G2AHDAC7 | |
| SCHEMBL9377287 | 0.89 | TAS1R3 (0.43) | TAS1R3TAS1R1PLA2G2C | |
| SCHEMBL19412266 | 0.87 | PLA2G2C (0.60) | PLA2G2CPLA2G2A | |
| SCHEMBL2666555 | 0.87 | PLA2G2C (0.60) | PLA2G2CPLA2G2A | |
| SCHEMBL17193095 | 0.87 | PLA2G2C (0.60) | PLA2G2CPLA2G2A | |
| SCHEMBL26637843 | 0.85 | TAS1R3 (0.41) | TAS1R3TAS1R1PLA2G2CPLA2G2A | |
| SCHEMBL19190505 | 0.85 | TAS1R3 (0.41) | TAS1R3TAS1R1PLA2G2CPLA2G2A | |
| SCHEMBL6547737 | 0.85 | PLA2G2C (0.62) | PLA2G2CPLA2G2A | |
| SCHEMBL20662884 | 0.84 | ALDH1A1 (0.48) | TAS1R3TAS1R1PLA2G2CPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4844717-A | KETONE AND AMIDE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-07-04 | — | — | US | claimed |
| US-4743273-A | AMIDE AND KETONE, ANTIDEPOSIT AGENTS | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-05-10 | — | — | US | claimed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| US-10286000-B2 | Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3431464-A2 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | Senomyx Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2018129405-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (nSMase2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20120015004-A1 | ENCAPSULATED SALTS AND USE IN HIGH ACID BEVERAGES | TROPICANA PRODUCTS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | RHODE ISLAND BOARD OF EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS | 2007-07-26 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-4844717-A | KETONE AND AMIDE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-07-04 | — | — | US | disclosed |
| US-4743273-A | AMIDE AND KETONE, ANTIDEPOSIT AGENTS | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015004-A1 | ENCAPSULATED SALTS AND USE IN HIGH ACID BEVERAGES | CEL, LIPC, LIPA | TAS1R3 993/4885TAS1R1 1081/4885PLA2G2C 82/4885 |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | TAS1R3 4440/4885TAS1R1 4630/4885PLA2G2C 447/4885 |
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | DSTYK, SRC, PTK2B | TAS1R3 2776/4885TAS1R1 3201/4885PLA2G2C 976/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | TAS1R3 3547/4885TAS1R1 3075/4885PLA2G2C 2400/4885 |
| US-10286000-B2 | Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer | RXRG, RXRA, RXRB | TAS1R3 734/4885TAS1R1 925/4885PLA2G2C 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.